Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
NCT06891560Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin in adenoid cystic carcinoma (ACC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT06891560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891560.